Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enhanced ALPP CAR-T in ALPP-Positive Advanced Solid Tumors
NCT07487597Phase 1Recruiting
- Sponsor
- TCRCure Biotech
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ALPP CAR-T in solid tumor, sponsored by TCRCure Biotech. Primary endpoint: Safety of Enhanced ALPP CAR-T cells at 24 months. Started Feb 2026; status: recruiting.
02
Drugs
ALPP CAR-T
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07487597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07487597.